Multidisciplinary Approaches to Minimally Invasive Cancer Treatment Using Colloidal Iodine: Twelve Case Reports in Digestive System

Norimasa Miura¹, Takehiko Wago² and Ryusuke Fujiki³*

*Corresponding author: Ryusuke Fujiki
Address: ¹PEZY-Pharma, Inc., Ono bld. 3F, 3-4-18 Mejiro, Toshima-ku, Tokyo 171-0031, Japan; ²YC Aoyama Clinic, YC bld.II 3F, 3-5-40 Kitaaoyama, Minato-ku, Tokyo 107-0061, Japan; ³Fujiki Hospital, 225 Ooishihara, Tateyama-cho, Nakashinkawa-gun, Toyama 930-0261, Japan
e-mail ☐ soumu@keijinkai-for.jp
Received: 27 October 2020; Accepted: 02 November 2020

ABSTRACT

Background: Iodine is a substance with a long history of medical application to human bodies. In addition, when targeting a tumor, the microenvironment is essential to improve the efficacy of cancer therapy. We attempted to examine the synergistic effect of colloidal iodine mainly on gastroenterological malignancies using low-dose-chemotherapy, hyperthermotherapy, and/or hyperbaric oxygen therapy.

Materials and Methods: Colloidal iodine was administered to 12 patients with unresectable in stage IV have an outcome that is treated with palliative medicine. who had already been diagnosed with an incurable, intractable advanced neoplasm, including pancreatic cancer, gastric cancer, esophageal cancer, cholangiocarcinoma, colon cancer, and end-stage rectal cancer. The route of administration was oral for 5 patients, intravenous for 7 patients, and topical for 2 patients. The effect was estimated using a change of tumor markers or/and the findings of endoscopy or computed tomography.

Results: By each modality to evaluate the effect, the addition of iodine successfully reduced tumor size and inhibited the progression of complications in all cases, compared with cases in previous studies treated without iodine. We also confirmed that intravenous infusion was a safe route of administration without adverse effects.

Conclusions: In this pilot study, twenty patients with advanced cancer who received treatment with colloidal iodine in nanoparticle status successfully inhibited tumor progression and improved ADL without adverse effects. As a multidisciplinary approach for both the cancer itself and its microenvironment, the complementary use of colloidal iodine may increase the rate of improvement of cancer via a biomodulating mechanism. This formulations may be useful as one of the multidisciplinary therapeutic modalities and we expect outcomes from the further phase of clinical trials.

Keywords: Colloidal Iodine, Cancer, Biomodulation, Multidisciplinary Therapy, Tumor Microenvironment

Introduction

Cancer is the leading cause of death. As the human population ages, it is speculated that the mortality rate from cancer will increase (Weir et al., 2015). Although anticancer drugs and molecularly targeted drugs, which directly attack cancer cells, are effective in cancer treatment, there are still limits to their effectiveness. In addition, many new therapeutic drugs such as immune checkpoint inhibitors are being developed (Hegde and Chen, 2020), but they are...
limited in the number of facilities where they can be administered, are expensive, have a narrow range of indications, and have adverse effects that physicians need to be aware of and manage (Baraibar et al., 2019). Furthermore, although advanced technologies such as cancer genome diagnosis have been developed, genomic cancer care is available only in a limited number of cancer centers (Cheng and Solit, 2018), and it will be some time before the general population can fully benefit from it. For patients with unresectable, intractable, and chemotherapy-resistant cancers who cannot be treated by cutting-edge medicine, physicians involved in hands-on care, including end-of-life care, are providing additional medical care, such as palliative care and are still searching for new, less invasive treatment strategies to increase therapeutic effect and response rates (Miura et al., 2019).

Because cancer comprises not just the cancer cells alone, to improve the response rate and treatment efficiency, it is important to regard cancer as organic aggregates of “cancer cells” and “all of the interstitial components (fibroblasts, vascular cells, various inflammatory cells, collagen found between cells, and physiological substances such as growth factors, cytokines, and chemokines) that make up a malignant tumor” (Locy et al., 2018).

The remarkable difference between biological and experimental cancers that clinicians face is in the tumor microenvironment (TME). Therefore, practicing medical doctors must take this fact into consideration when treating them (Shimizu et al., 2018). The importance of TME has drawn more attention recently because a treatment that targets the malignant TME induces less therapy-resistance and adverse effects.

Based on this treatment strategy, we conducted a clinical study to evaluate the effectiveness of a biomodulating cancer therapy using colloidal iodine as well as low dose chemotherapy (Bontempo et al., 2017), hyperthermotherapy (Multhoff et al., 2016; Evans et al., 2015), and hyperbaric oxygen (HBO) therapy (Moen and Stuhr, 2012; Stępień et al., 2016). Clinical trial for stage II breast cancer (ClinicalTrials.gov: #NCT03688958; https://clinicaltrials.gov/) was completed with very positive results. This formulation including colloidal iodine was approved for clinics only in Sri Lanka and is currently under review for FDA approval. We attempted to confirm the usefulness of concomitant therapy with low dose chemotherapy/hyperthermotherapy/HBO therapy using colloidal iodine in this pilot study (Ohguri et al., 2009; Bosco et al., 2013).

**Methods**

This trial included 12 patients with unresectable advanced cancer who had already been diagnosed with incurable. The list of patients enrolled in this study is shown in Table 1.

Colloidal iodine (JCI MN Colloidal Iodine®) was either provided or purchased for clinical use by the JCI Center (JCIC; Nihonbashi, Tokyo, Japan). The formulations for oral or
intravenous injection contained colloidal iodine (12.2 mg/ml) in a water solution. The formulation for direct topical use by endoscopy were the same as that for oral administration. The oral ingestion dose was 160 mL/day for 30 days or longer. The intravenous infusion dose was 200 mL/dose, once daily for 10 days or more, according to the information provided by the manufacture.

Table 1: Clinical characteristics and treatment of the patient

<table>
<thead>
<tr>
<th>Case</th>
<th>Age</th>
<th>Gender</th>
<th>Malignant disease</th>
<th>Therapy</th>
<th>JCI MN IODINE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>52</td>
<td>M</td>
<td>unresectable rectal cancer with lung metastasis</td>
<td>XELOX / hyperthermia / HBO</td>
<td>i.v. once/day (10D)</td>
</tr>
<tr>
<td>2</td>
<td>81</td>
<td>F</td>
<td>unresectable gastric cancer</td>
<td>TS-1 80mg/day / hyperthermia / HBO</td>
<td>p.o. twice/day (10D)</td>
</tr>
<tr>
<td>3</td>
<td>95</td>
<td>M</td>
<td>unresectable gastric cancer</td>
<td>nab-paclitaxel 120mg/day / hyperthermia / HBO</td>
<td>i.v. twice/day (10D) + directly</td>
</tr>
<tr>
<td>4</td>
<td>70</td>
<td>M</td>
<td>unresectable scirrhous gastric cancer with liver metastasis</td>
<td>TS-1 80mg/day / hyperthermia / HBO</td>
<td>p.o. twice/day</td>
</tr>
<tr>
<td>5</td>
<td>79</td>
<td>F</td>
<td>unresectable gastric cancer</td>
<td>nab-paclitaxel 120mg/day (1d) / hyperthermia / HBO (6d)</td>
<td>p.o. twice/day (10D)</td>
</tr>
<tr>
<td>6</td>
<td>83</td>
<td>M</td>
<td>unresectable esophageal cancer</td>
<td>nab-paclitaxel 120mg/day + CBDCA 150mg (twice/6 wks.) / hyperthermia</td>
<td>i.v. once/day (10D)</td>
</tr>
<tr>
<td>7</td>
<td>75</td>
<td>F</td>
<td>unresectable pancreatic cancer</td>
<td>nab-paclitaxel 120mg/day + CBDCA 150mg (twice/6 wks.) / hyperthermia</td>
<td>i.v. once/day (10D)</td>
</tr>
<tr>
<td>8</td>
<td>64</td>
<td>M</td>
<td>intrahepatic cholangiocarcinoma</td>
<td>nab-paclitaxel 120mg/day + oxalplatin 150mg (twice/6 wks.) / hyperthermia</td>
<td>p.o. twice/day (10D) + 0.4×p.o. once/day (30D)</td>
</tr>
<tr>
<td>9</td>
<td>72</td>
<td>M</td>
<td>gastric cancer with liver metastasis</td>
<td>nab-paclitaxel 120mg/day + ramucirumab / hyperthermia / HBO</td>
<td>i.v. twice/day (10D)</td>
</tr>
<tr>
<td>10</td>
<td>62</td>
<td>M</td>
<td>recurrence of rectal cancer after surgical treatment</td>
<td>XELOX + bevacizumab (2 cool) / hyperthermia / HBO</td>
<td>i.v. twice/day (14D)</td>
</tr>
<tr>
<td>11</td>
<td>82</td>
<td>F</td>
<td>recurrence of transverse colon cancer after surgical treatment</td>
<td>XELOX + bevacizumab / capetitabine / hyperthermia / HBO /</td>
<td>p.o. twice/day (10D) + topically</td>
</tr>
<tr>
<td>12</td>
<td>61</td>
<td>M</td>
<td>scirrhous gastric cancer with ascites and peritoneal dissemination</td>
<td>nab-paclitaxel 120mg/day + ramucirumab / hyperthermia / HBO</td>
<td>p.o. twice/day (10D)</td>
</tr>
</tbody>
</table>

M: male, F: female, N/A: not applicable, hyperthermia: hyperthermotherapy, D: days, p.o.: per os, i.v.: intraven

In these cases, we investigated whether colloidal iodine manufactured by JCIC could improve the therapeutic effect on cancer by regulating the biomodulation in the cancer environment. In detail, we used JCI MN colloidal iodine along with the 3 modalities of low dose chemotherapy, hyperthermotherapy, and HBO therapy. Colloidal iodine was administered orally, directly, or intravenously depending on the condition of the patient. The efficacy was assessed by blood tests, computed tomography (CT) or endoscopic after one or two months. Multidisciplinary treatment mainly for gastrointestinal malignancies has been used in Fujiki Hospital for a wide variety of cancers, including pancreatic cancer, gastric cancer, esophageal cancer, cholangiocarcinoma, rectal cancer, and end-stage colon cancer (Cheng et al., 2019). The number of patients was 1, 6, 1, 1, 2, and 1, respectively. All patients with advanced cancer in terminal status were pre-registered and enrolled in from 2015 to 2018.
and considered to have satisfied the inclusion criteria. All patients approved this project after informed consent. The registration number in our hospital is #FH201501.

Hyperthermotherapy was induced in the tumor tissue by elevating the temperature to $42 - 50^\circ C$ for 0.5–1 h using a Thermotron RF-8 GR edition (Vinita Co., Ltd., Osaka, Japan) (Multhoff et al., 2016).

Hyperbaric oxygen therapy delivered 100% oxygen to the patient’s pulmonary system using a Model 3300HJ (Hokkaido Air Water Inc., Sapporo, Japan) (Stępień et al., 2016). The patients breathed oxygen at levels far greater than 21%, which is found at a normal level atmosphere. Low dose chemotherapy was chosen to minimize the adverse effects and the pain of patients. XELOX (capecitabine/oxaliplatin), TS-1 (tegafur/gimeracil/oteracil potassium), nab-paclitaxel, CBDCA (carboplatin), oxaliplatin, capecitabine, ramucirumab, or/and bevacizumab was chosen in consideration of the clinical stage of disease, anticancer drug use history, and tolerance in the elderly. This study was submitted the proper protocol to and approved by the respective patient and family because the safety of these modalities has been clinically confirmed and all patients were in dangerously ill condition.

Results

The clinical course in respective cases is summarized in Table 2. Briefly, in all cases, an extension of the non-proliferation period, reduction of tumor size, and improvement of physical conditions and ADL (activities of daily living) could be seen. The direct topical effect of colloidal iodine infusion therapy by washing the mucosal lesions of tumor was found to increase the response rate and therapeutic effect of low-dose chemotherapy, hyperthermotherapy, and hyperbaric oxygen therapy. Colloidal iodine was safe to administer and had no adverse effects. In the case of bleeding, a hemostatic effect by washing the bleeding area was confirmed (cases 1–3) (Fig. 1). An improvement of mucosal lesions of scirrhous gastric carcinoma was observed (case 4) (Fig. 2). Biomarkers or tumor markers showed a remarkable reduction or improvement (cases 6, 7, and 12) during this collective therapy. Endoscopic findings (Fig. 1-2) and CT (Fig. 3-4) showed the suppression of tumor progression. Stenosis by cancer progression could not be found for gastroenterological and hepatobiliary diseases (cases 1–12). Intravenous infusion as well as oral administration was effective for gastric cancer, esophageal cancer, pancreatic cancer, cholangiocarcinoma, and intractable cancer with liver metastasis, (cases 1, 3, 6, 7, and 9). These formulations had a reduction effect on pancreatic cancer in stage 4 and diffuse cholangiocarcinoma within 8 weeks (Fig. 3). Tumor lysis syndrome was observed in case 9. The tumor with a KRAS mutation initially enlarged in size before shrinking during the treatment in case 10, and a prominent reduction of tumor size and a surprisingly improved fistula generated by cancer progression was confirmed by topical administration in case 11 within 4 weeks (Fig. 4). In case 12, with peritoneal dissemination and
intractable ascites, replacement therapy of ascites (less than pH 7.3) with colloidal iodine (pH 8.5) induced no recurrence of ascites (Fig. 4). No adverse effects such as fever, skin rash, lymphadenopathy, or pain at the lesion site were observed in any case.

Table 2: The clinical course of the patient

<table>
<thead>
<tr>
<th>Case</th>
<th>Clinical course of each case</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Giant tumor lesions with hemorrhage shrink approximately 50% after 1 month of treatment and only a few lesions after 3 months. Melena was no longer evident. Intra-abdominal lymph node metastases showed improvement, although there was no increase in lung and spine metastases.</td>
</tr>
<tr>
<td>2</td>
<td>Significant reduction of tumor lesions and hemostatic effect were observed. Oral intake was also available from the third week after treatment.</td>
</tr>
<tr>
<td>3</td>
<td>The concomitant use of colloidal iodine infusion therapy resulted in significant reduction of the tumor lesion and hemostasis in just 2 weeks.</td>
</tr>
<tr>
<td>4</td>
<td>One month later, the unevenness of the stomach lining disappeared, and three months later, the mucosal lesions almost disappeared. Liver metastases were unchanged.</td>
</tr>
<tr>
<td>5</td>
<td>Gastric endoscopy showed marked topical improvement of the lesion.</td>
</tr>
<tr>
<td>6</td>
<td>The reduction in esophageal tumor and improvement in stenosis status and tumor markers were observed, leading to the improvement in his food intake status.</td>
</tr>
<tr>
<td>7</td>
<td>CT images and tumor marker CA19-9 showed a significant reduction in tumor size and a reduction from 2350 to 148, respectively.</td>
</tr>
<tr>
<td>8</td>
<td>Four weeks after treatment, a remarkable improvement in the CT images was observed. There were no adverse effects associated with the treatment.</td>
</tr>
<tr>
<td>9</td>
<td>Approximately one month later, a significant reduction of the liver metastatic lesion was observed, resulting in the concomitant tumor collapse syndrome.</td>
</tr>
<tr>
<td>10</td>
<td>A cessation of enlargement and reduction of the intrapelvic tumor were observed.</td>
</tr>
<tr>
<td>11</td>
<td>About one month after colloidal iodine was injected into the fistula in the peritoneum and abdominal wall and washed repeatedly, the abdominal wall fistula was closed and the tumor volume was markedly reduced to approximately 40%.</td>
</tr>
<tr>
<td>12</td>
<td>Approximately one month after treatment, she could walk on her own, take orally and was discharged from the hospital. After the replacement of ascites with 1500 ml of colloidal iodine solution, no ascites effusion was observed.</td>
</tr>
</tbody>
</table>

Figure 1: Endoscopic images showing the clinical course for case 1 to case 3. In case 1, the progressive semicircular rectal cancer with mucosal oozing gradually improved at 12 weeks after intravenous administration. In case 2, the advanced gastric cancer with blood clotting, an ulcerated surface, and a white moss improved from a continuous to non-continuous lesion in 8 weeks following the oral and daily administration. In case 3, the Borrmann type III gastric cancer with oozing shrunk in size, and the surrounding mucosa appeared to be converted to a normal mucosa.
Figure 2: Endoscopic images showing the clinical course for case 4 to case 6. In case 4, the scirrhou胃 carcinorna at the anterior wall of the lower body of the stomach gradually changed to a normal mucosa at 12 weeks but only by oral intake of iodine. In case 5, the antral carcinoma showed a gradual change at 4 weeks. In case 6, the advanced esophageal carcinoma at the middle thoracic esophagus (Mt) with oozing and ulceration improved from a cancer-infiltrating mucosa to a mucosa without unevenness, but faintly with oozing and ulceration.

Figure 3: CT images showing the clinical course of case 7 and case 8. In case 7, the mass of tumor in the uncus of the pancreas in stage 4 shrank more than 50% at 4 weeks after intravenous administration of iodine. In case 8, the occupied area of the unresectable cholangiocarcinoma reduced in size at 8 weeks by oral intake.
Multidisciplinary Approaches to Minimally Invasive Cancer Treatment Using Colloidal Iodine: Twelve Case Reports in Digestive System

Figure 4: CT images showing the clinical course for case 9 to case 12. In case 9, the improvement of rectal cancer with liver metastasis was confirmed at 4 weeks after intravenous infusion. In case 10, the reduction of intrapelvic mass was observed at 4 weeks. In case 11, the intraperitoneal mass with a fistula on the abdominal wall was effectively treated with the topical and oral administration of iodine, resulting in shrinkage of the tumor mass. In case 12, severe ascites with the progression of gastric cancer disappeared a week later by the replacement of ascites with an iodine preparation.

Discussions

Iodine is an element of the halogen group with atomic number 53 and is one of the essential minerals of thyroid hormones in humans (Bernet, 2019). It is particularly abundant in seaweed, and we get it from our diet into our bodies. Approximately 30% of the world's population is said to be iodine deficient, and iodine deficiency can cause mental developmental delays, hypothyroidism, cretinism, and growth and developmental abnormalities (Benoist et al., 2004; Verheesen and Schweitzer, 2008; Shelanski and Shelanski, 1956; Galofré et al., 1994a).

Iodine as a drug, such as an iodine tincture and povidone iodine, is familiar in our daily lives as a disinfectant for the skin and throat (Shelanski and Shelanski, 1956), and its sterilizing effect on viruses is particularly remarkable (Bianco et al., 2002). However, because iodine itself is highly toxic, these products can be used to disinfect and sterilize the surface of the skin and mucous membranes, but cannot be taken into the body (Galofré et al., 1994a; Galofré et al., 1994b).

Minimally invasive combined therapy with colloidal iodine (JCI MN Iodine®) is attracting worldwide attention as a future cancer treatment method (Yokoyama, 2018). This formulation adds iodine ions to the blood, which are taken up by the thyroid gland to become thyroid hormones (Dentice et al., 2013). Iodine is then released as a protein-binding thyroid hormone and is supplied to the whole body (Hays and Solomon, 1965; Nicola et al., 2009).
Although the absorption rate of iodine is dramatically higher due to colloidization (Schubert and Chanana, 2019), excess iodine (Galofré et al., 1994a; Leung and Braverman, 2014), which is not involved in hormone synthesis, is rapidly excreted as iodine ions. Therefore, it does not continue to accumulate in the body like common drugs, has no tolerance, is highly safe, and minimizes the possibility of iodine-induced toxicity. However, physicians should be careful at present when administrating to patients with hyperthyroidism, Hashimoto disease, or viral infections except for the cold virus.

Direct topical administration is a useful method of administration for the cancer environment (Gulaboglu et al., 2005) and contributes to the shrinking effect on the tumor itself (Aceves et al., 2013). These are unique formulations with a nanoparticle coating that allows iodine to be safely taken into the body without iodine allergy. The formulations can be applied to examine the pharmacological effects on cancer or intractable diseases so that we can use them safely in clinical trials (Venturi et al., 1993). In contrast, colloidal iodine in practical cancer therapy is absorbed into the blood as an iodine ion, and acts, as its main mode of action, as iodine contained in protein-binding thyroid hormones. Iodine acts directly on peripheral blood lymphocytes to regulate T cell proliferation and differentiation, cytokine production, and IgE production (Spitzweg et al., 2000) and acts on fibroblasts to inhibit IL4 and TNFα activation and protect organs from tissue damage (Iwata et al., 2014). Also, by inhibiting the degradation of cancer inhibitory genes by cancer tumor proteins, G2-M arrest in the cell cycle is promoted along with tumor suppressor gene-dependent apoptosis, which potentiates the effects of chemotherapy (Arroyo-Helguera et al., 2008). We presume that colloidal iodine acts by binding to tumor suppressor genes via a molecular chaperone mechanism, resulting in stabilization of the complex and enhancing other anticancer therapies (Arvan et al., 1997). Iodine removes the activated oxygen created by mitochondria to enhance cell regeneration (Chaiyabutr and Jakobsen, 1978). Furthermore, it forms a conjugate with inflammatory cytokines (Spitzweg et al., 2000) and tumor proteins that are fragmented by chemotherapy, inactivating the cells and proteins and attenuating the multi-drug resistance to chemotherapy (Supawat et al., 2019).

Iodine-125 low-dose-rate (LDR) brachytherapy for prostate cancer has been demonstrated to induce effective immune responses in patients. The gradual and bimodal increase of activated T cells (CD3+, CD4+, and CD8+) may contribute to the maintenance of remission and reduction of relapse rates. Iodine has strong intermolecular aggregation properties due to van der Waals forces, is made into “iodine + water molecule aggregates”, and functions as an intracellular antioxidant (Rosenholm et al., 2008). Free iodine (I₂) oxidizes water to become hypiodine and hydrogen iodide and efficiently scavenges intracellular hydroxyl radicals. It is particularly effective in eliminating mitochondria-derived reactive oxygen species (ROS) (Lin et al., 2019). This action restores mitochondrial function, followed
by changing the anaerobic environment of cancer cells to an aerobic one and allowing the cells to be reset.

Hyperthermotherapy has anticancer effects because the formation of an HSP-complex, which activates oncogenes, is suppressed. The formulations with intermolecular forces have a high affinity for proteins such as HSP and oncogenes, leading to the inactivation of oncogenes, similar to the process of hyperthermia (Mahmood et al., 2018). Furthermore, molecular motions in a colloidal dispersion system become more reactive as temperature rises, and the iodine ion can easily penetrate into cancer cells (Kogai et al., 2000; Klotz and Benz, 1993), followed by the inhibition of cancer growth. This suggests the possibility of iodine as a sensitizing agent to increase the effects of thermal therapy.

In HBO therapy, arterial oxygen concentrations increase to 6-fold those of ordinary conditions. This allows induction of the cancer's TME from an anaerobic to an aerobic environment. This decreases the genetic diversity of cancers induced by low oxygen states. Recent reports have maintained that the main target of carcinogenesis may be in DNA but in mitochondria of cytoplasm (Watanabe, 2015; Zhou et al., 2000). Iodine also enhances cell regeneration by activating the cell mitochondria damaged by cancer tissue, colon tissue, cerebral infarction, or myocardial infarction to assist in recovery from these conditions (Iwata et al., 2014; Supawat et al., 2019; Aranda et al., 2013). In synergy with HBO therapy, it turns cellular anaerobic metabolism of cancer cells into aerobic metabolism, inhibiting the proliferation of cancer.

As a direct effect of colloidal iodine, we focused on the effect of replacement therapy of ascites with an alkaline formulation. This technique decreases the number of cancer-associated fibroblasts (CAF) (Shimoda et al., 2010; Moreno-Vega et al., 2019), which are the leading instigator in creating an intraperitoneal inflammatory environment, and helps reduce tumor-facilitating exosome miRNA and inflammatory cytokine production (Spitzweg et al., 2000), thus improving the TME. We experienced cases sensitive to the tissue environment with effectiveness on refractory decubitus, skin ulcers, and skin fistulas for just a short time. In the current clinical trial, these formulations not only inhibited the exacerbation of malignant diseases but also reduced tumor mass, although reports have suggested that thyroid hormones promote the growth of colon cancer (Lee et al., 2018; Catalano et al., 2016).

Thus, iodine suppresses inflammation (Beukelman et al., 2008) and improves the microenvironment of cancer (Bigoni-Ordóñez et al., 2018). By improving tissue metabolism by restoring mitochondrial function (Yu et al., 2018), it exerts anti-cancer effects through improved sugar metabolism and its anti-inflammatory and anti-allergy properties (Nava-Villalba et al., 2015). Iodine also has bactericidal and anti-viral effects. It is well-known that 0.5% iodine as a disinfectant agent is most effective on viruses (influenza: H3N2, H3N2, H1N1;
coronavirus, RS virus, adenovirus) compared with other antiviral agents and reduces them to below the detection limit after 15 s (Shelanski and Shelanski, 1956). The new type of coronavirus (COVID-19), which has caused a stir in the world, is an envelope virus with a single positive-strand RNA as its viral genome (Kaushal et al., 2020), and, like the SARS coronavirus, is transmitted to human cells through the ACE2 receptor. The colloidal iodine agent has a high affinity for proteins even for viral proteins. The colloidal form of the drug has various uses, not only for cancer treatment, but also for improving tissue absorption, suggesting that iodine has potential as a counter-COVID-19 agent.

Currently, colloidal iodine is administered as an intravenous drip solution, an oral solution, or an inhalation solution (Okamoto et al., 2018). In addition, eye and nasal drops of iodine have a high possibility of preventing viral infections (Heimbuch et al., 2015). For patients with mild illnesses, prescription of oral solutions at home or inhalation solutions with a portable nebulizer can reduce the burden on the medical scene without even requiring a hospital visit.

Colloidal iodine is a novel biomodulating therapy (Bilal et al., 2017) that can support the effects of conventional anti-drugs or checkpoint inhibitors with a supplemental mechanism of action. Biogenetical modulation (BGM) regulates the formation of the gene-cancer protein complex, inhibits activation of oncogenes, and prevents decreased functioning of the tumor suppressor genes (Furth, 2012). BGM, thus, allows a marked improvement of response rates and therapeutic effect when used concomitantly with hyperthermotherapy and HBO therapy. Because colloidal iodine has a biochemical modulation (BCM) effect on chemotherapy, its use may serve to minimize or overcome the adverse effects of chemotherapy. Biomodulation (BM) effect is the overall effect comprising BGM, BCM, and biological modulation. We speculated that this BM effect is the main mechanism of action of colloidal iodine agents. Colloidal iodine with the stability of a biocompatible nanoparticle coating has a BM effect and contributes to improving the effectiveness of cancer treatment. Also, we expect that iodine will improve the sensitivity of molecular targeting chemotherapy via its action on the TME (Bhatt et al., 2017), because this therapy makes the subsequent molecular-targeting therapies possible by improving physical status of patients.

**Conclusions**

For the most effective strategy using this formulation, we should determine the duration and optimal dose of treatment to target or modulate the TME. Our findings will have a strong impact on future cancer treatment, although a multidisciplinary cancer treatment will be needed because the molecules that play a central role in the TME vary for different organs. This trial suggests the usefulness of colloidal iodine in the early stages of cancer in further clinical trials of this preparation.
Miura N et al., Multidisciplinary Approaches to Minimally Invasive Cancer Treatment Using Colloidal Iodine: Twelve Case Reports in Digestive System

Abbreviations

HBO: Hyperbaric Oxygen; BM: Biomodulation; CT: Computed Tomography Scan; XELOX Capecitabine/Oxaliplatin; TS-1: Tegafur/Gimeracil/Oteracil Potassium; CBDCA Carboplatin; ADL: Activities Of Daily Living; COVID-19: the new type of coronavirus; SARS: Severe Acute Respiratory Syndrome; HSP: Heat Shock Protein

Acknowledgments

We all deeply thank for all doctors and paramedical stuffs working at Fujiki Hospital.

Declarations

Ethical approval and Consent to participate

All patients approved this project after informed consent.

Data Availability

The authors declare that all other data supporting the findings of this study are available within the article.

Authors Contributions

The author(s) have made the following declarations regarding their contributions: RF conceived and designed the experiments. TW and NM analyzed the data and wrote this manuscript. NM and RF approved the final manuscript. All authors read and approved the final manuscript.

Funding Support

N/A

Availability of Data and Materials

The datasets generated for this study are available from the corresponding author on reasonable request.

Consent for Publication

Not applicable.

Competing Interests

All authors are aware of the consent and agree with the submission. The authors declare no conflict of interest or competing interests.
References


Bernet VJ. Thyroid hormone misuse and abuse. *Endocrine* 2019; 66: 79–86.


Global Journal of Cancer Case Reports | November 2020 | Volume 01 | Issue 02 | PAGE 1-15

Miura N *et al.*, Multidisciplinary Approaches to Minimally Invasive Cancer Treatment Using Colloidal Iodine: Twelve Case Reports in Digestive System

DOI: http://dx.doi.org/10.47733/GJCCR.2020.1206

http://www.cancercasereports.com/


